Cabaletta Bio Newsroom

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Yahoo FinanceOct 30 23:16

State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings

Yahoo FinanceOct 18 03:06

Kyverna, Cabaletta Started at Buys by UBS on CAR T Therapy Potential

Seeking AlphaOct 11 02:04

UBS Initiates Cabaletta Bio(CABA.US) With Buy Rating, Announces Target Price $10

Futu NewsOct 10 18:31 · Ratings

Cabaletta Bio Outlines Future Trials and Development Strategy

TipRanksOct 7 18:30

Stifel Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $26

Futu NewsSep 26 20:31 · Ratings

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

GlobeNewswireSep 26 04:30

HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target

BenzingaSep 17 19:32 · Ratings

H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25

H.C. Wainwright analyst Douglas Tsao maintains $Cabaletta Bio(CABA.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 45.4%

Futu NewsSep 17 18:31 · Ratings

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Simply Wall StSep 6 23:49

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

newsfilter.ioAug 28 20:00

Evercore ISI Cuts Price Target on Cabaletta Bio to $15 From $25, Keeps Outperform Rating

MT NewswiresAug 26 19:25 · Ratings

Several Headwinds Dragged Cabaletta Bio (CABA) in Q2

Yahoo FinanceAug 21 16:32

Wells Fargo Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $20

Wells Fargo analyst Derek Archila maintains $Cabaletta Bio(CABA.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 47.3% and

Futu NewsAug 20 20:33 · Ratings

Buy Rating Affirmed for Cabaletta Bio Amid Superior CD19 CAR T Therapy Efficacy in Autoimmune Disease Treatment

TipRanksAug 20 19:37 · Ratings

Cabaletta Bio Is Maintained at Overweight by Wells Fargo

Dow JonesAug 13 01:51

Cabaletta Bio Price Target Cut to $20.00/Share From $35.00 by Wells Fargo

Dow JonesAug 13 01:51 · Ratings

Evercore ISI Group Maintains Outperform on Cabaletta Bio, Lowers Price Target to $15

BenzingaAug 12 21:57 · Ratings

Cabaletta Bio: Overweight Rating Maintained Amidst ICANS Incident and Adjusted Price Target

TipRanksAug 12 18:41 · Ratings

Express News | Cabaletta Bio Inc - Evercore ISI Cuts Target Price to $15 From $25

BreakingsAug 12 13:45